<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746330</url>
  </required_header>
  <id_info>
    <org_study_id>CMFF258C2204</org_study_id>
    <nct_id>NCT00746330</nct_id>
  </id_info>
  <brief_title>Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Multi-centre, 4-way Cross-over Study to Compare the Single Dose Bronchodilatory Effect of Formoterol Fumarate in Combination With Mometasone Furoate Delivered Via Pressurized Metered Dose Inhaler (pMDI) to Placebo Delivered Via pMDI in Children Aged 5-11 Years Old With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the pharmacodynamics (bronchodilation, onset and
      duration of action), of a single dose of formoterol fumarate in combination with mometasone
      furoate to placebo in children of 5-11 years with persistent asthma. The study will also
      assess the bronchodilatory effect of a single dose of formoterol fumarate alone and in
      combination with mometasone furoate delivered via a pressurized metered dose inhaler (pMDI)
      to the bronchodilatory effect of formoterol fumarate delivered via a dry powder inhaler
      (DPI). Furthermore, pharmacokinetic assessments of plasma and urine will also be conducted
      throughout the study to assess systemic exposure following administration of the study
      medication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment</measure>
    <time_frame>From 0 to 12 Hours (0-12h) post-dose, after each treatment administered (approximately 1 treatment a week for 4 weeks of treatment).</time_frame>
    <description>For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</measure>
    <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
    <description>All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</measure>
    <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
    <description>All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</measure>
    <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
    <description>All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)</measure>
    <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
    <description>Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)</measure>
    <time_frame>0 to 3 hrs and 0-12 hrs</time_frame>
    <description>Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>F12M - PL - F12D - MFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F12D - F12M - MFF - PL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MFF - F12D - PL - F12M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PL - MFF - F12M - F12D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate/formoterol fumarate (MFF)</intervention_name>
    <description>Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.</description>
    <arm_group_label>F12M - PL - F12D - MFF</arm_group_label>
    <arm_group_label>F12D - F12M - MFF - PL</arm_group_label>
    <arm_group_label>MFF - F12D - PL - F12M</arm_group_label>
    <arm_group_label>PL - MFF - F12M - F12D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol fumarate 12 μg pMDI (F12M)</intervention_name>
    <description>Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).</description>
    <arm_group_label>F12M - PL - F12D - MFF</arm_group_label>
    <arm_group_label>F12D - F12M - MFF - PL</arm_group_label>
    <arm_group_label>MFF - F12D - PL - F12M</arm_group_label>
    <arm_group_label>PL - MFF - F12M - F12D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol fumarate 12 μg DPI (F12D)</intervention_name>
    <description>Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).</description>
    <arm_group_label>F12M - PL - F12D - MFF</arm_group_label>
    <arm_group_label>F12D - F12M - MFF - PL</arm_group_label>
    <arm_group_label>MFF - F12D - PL - F12M</arm_group_label>
    <arm_group_label>PL - MFF - F12M - F12D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to F12D</intervention_name>
    <description>Placebo to formoterol fumarate DPI delivered via DPI</description>
    <arm_group_label>F12M - PL - F12D - MFF</arm_group_label>
    <arm_group_label>F12D - F12M - MFF - PL</arm_group_label>
    <arm_group_label>MFF - F12D - PL - F12M</arm_group_label>
    <arm_group_label>PL - MFF - F12M - F12D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to F12M/MFF</intervention_name>
    <description>Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI</description>
    <arm_group_label>F12M - PL - F12D - MFF</arm_group_label>
    <arm_group_label>F12D - F12M - MFF - PL</arm_group_label>
    <arm_group_label>MFF - F12D - PL - F12M</arm_group_label>
    <arm_group_label>PL - MFF - F12M - F12D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  5 to 11 years of age of either sex and of any race

          -  A diagnosis (according to the Global Initiative for Asthma [GINA] guidelines) of
             persistent asthma for a period of at least 6 months prior to screening and must have
             been on a stable asthma regimen (daily dose unchanged) for at least 4 weeks prior to
             screening

          -  β2-agonist reversibility, defined as an increase in absolute FEV1 of ≥12% within 30
             minutes after administration of 200μg of salbutamol without the use of a spacer or its
             equivalent in accordance with ATS/ERS standards

          -  A child must have an FEV1 of ≥ 60% and ≤ 90% of Polgar predicted when all restricted
             medications have been withheld for the appropriate intervals

        Exclusion Criteria:

          -  Use of other investigational drugs at the time of enrolment, or within 30 days or 5
             half-lives of enrolment, whichever is longer.

          -  History of malignancy of any organ system within past 5 years.

          -  Pre-dose change (increase or decrease) in absolute FEV1 of 15% at Visit 2, compared
             with value at screening.

          -  Hospitalized or had an emergency room treatment for an acute asthma exacerbation in
             the 1 month prior to Visit 1, or who had a clinical deterioration of asthma between
             Visits 1 and 2 that resulted in emergency treatment, hospitalization, or treatment
             with excluded asthma medication.

          -  Significant medication condition or situation.

          -  QTc &gt; 440 msec (boys) or &gt; 450 msec (girls) on electrocardiogram(ECG) assessment at
             screening.

          -  Upper or lower respiratory tract infection within 4 weeks prior to screening.

          -  Chronic conditions affecting the respiratory tract or chronic lung diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Peru</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <results_first_submitted>November 21, 2010</results_first_submitted>
  <results_first_submitted_qc>March 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 14, 2011</results_first_posted>
  <last_update_submitted>June 3, 2011</last_update_submitted>
  <last_update_submitted_qc>June 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Children</keyword>
  <keyword>Persistent asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>F12M, PL, F12D, MFF</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via Pressurized Metered Dose Inhaler (pMDI) + placebo to formoterol fumarate via Dry Powder Inhaler (DPI); Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="P2">
          <title>F12D, F12M, MFF, PL</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="P3">
          <title>MFF, F12D, PL, F12M</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="P4">
          <title>PL, MFF, F12M, F12D</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>F12M, PL, F12D, MFF</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="B2">
          <title>F12D, F12M, MFF, PL</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="B3">
          <title>MFF, F12D, PL, F12M</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="B4">
          <title>PL, MFF, F12M, F12D</title>
          <description>Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="1.63"/>
                    <measurement group_id="B2" value="9.4" spread="1.51"/>
                    <measurement group_id="B3" value="7.9" spread="1.83"/>
                    <measurement group_id="B4" value="10.1" spread="1.21"/>
                    <measurement group_id="B5" value="9.1" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment</title>
        <description>For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose</description>
        <time_frame>From 0 to 12 Hours (0-12h) post-dose, after each treatment administered (approximately 1 treatment a week for 4 weeks of treatment).</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MFF10</title>
            <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
          </group>
          <group group_id="O2">
            <title>F12M</title>
            <description>Formoterol fumarate 12 μg via pMDI/ Placebo via DPI</description>
          </group>
          <group group_id="O3">
            <title>F12D</title>
            <description>Placebo via pMDI/ Formoterol fumarate 12 μg via DPI</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo via pMDI/ Placebo via DPI</description>
          </group>
        </group_list>
        <measure>
          <title>The Standardized Forced Expiratory Volume in 1 Second (FEV1) Using Area Under the Curve (AUC) From 0 to 12 Hours (0-12h) Post-dose by Treatment</title>
          <description>For FEV1 AUC(0-12h) the trapezoidal rule was applied using planned time measurements to calculate the AUC up to and including the last measurement recorded before intake of rescue medication. The AUC was standardized by dividing by the length of time for which measurements of FEV1 were included in the calculation of the AUC thus adjusting for subjects who were unable to complete the measurements during the 12-hour observation period and without inhaling rescue medication. The unit of the AUC was in L, being a weighted average of the acceptable FEV1 measurements recorded over 12 hours post dose</description>
          <population>Full Analysis Set</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread=".042" lower_limit="1.69" upper_limit="1.86"/>
                    <measurement group_id="O2" value="1.77" spread=".042" lower_limit="1.69" upper_limit="1.85"/>
                    <measurement group_id="O3" value="1.80" spread=".042" lower_limit="1.72" upper_limit="1.89"/>
                    <measurement group_id="O4" value="1.71" spread=".042" lower_limit="1.62" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</title>
        <description>All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.</description>
        <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MFF10</title>
            <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
          </group>
          <group group_id="O2">
            <title>F12M</title>
            <description>Formoterol fumarate 12 μg via pMDI/ Placebo via DPI</description>
          </group>
          <group group_id="O3">
            <title>F12D</title>
            <description>Placebo via pMDI/ Formoterol fumarate 12 μg via DPI</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo via pMDI/ Placebo via DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Serial FEV1 Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</title>
          <description>All efficacy evaluations were based on spirometry assessments of lung function. FEV1 is the maximum amount of air expired in one second. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the (ATS / ERS) standards.</description>
          <population>Full Analysis Set</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit="1.70" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.77" lower_limit="1.72" upper_limit="1.81"/>
                    <measurement group_id="O3" value="1.77" lower_limit="1.73" upper_limit="1.82"/>
                    <measurement group_id="O4" value="1.68" lower_limit="1.63" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.75" upper_limit="1.84"/>
                    <measurement group_id="O2" value="1.80" lower_limit="1.75" upper_limit="1.85"/>
                    <measurement group_id="O3" value="1.82" lower_limit="1.77" upper_limit="1.87"/>
                    <measurement group_id="O4" value="1.69" lower_limit="1.64" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour (N=32, 31, 29, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="1.75" upper_limit="1.87"/>
                    <measurement group_id="O2" value="1.80" lower_limit="1.74" upper_limit="1.86"/>
                    <measurement group_id="O3" value="1.86" lower_limit="1.79" upper_limit="1.92"/>
                    <measurement group_id="O4" value="1.72" lower_limit="1.66" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="1.74" upper_limit="1.87"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.72" upper_limit="1.85"/>
                    <measurement group_id="O3" value="1.85" lower_limit="1.79" upper_limit="1.91"/>
                    <measurement group_id="O4" value="1.73" lower_limit="1.67" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" lower_limit="1.73" upper_limit="1.88"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.71" upper_limit="1.87"/>
                    <measurement group_id="O3" value="1.84" lower_limit="1.76" upper_limit="1.92"/>
                    <measurement group_id="O4" value="1.72" lower_limit="1.64" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.69" upper_limit="1.83"/>
                    <measurement group_id="O2" value="1.75" lower_limit="1.69" upper_limit="1.82"/>
                    <measurement group_id="O3" value="1.79" lower_limit="1.72" upper_limit="1.86"/>
                    <measurement group_id="O4" value="1.70" lower_limit="1.63" upper_limit="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.67" upper_limit="1.78"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.65" upper_limit="1.76"/>
                    <measurement group_id="O3" value="1.76" lower_limit="1.70" upper_limit="1.81"/>
                    <measurement group_id="O4" value="1.66" lower_limit="1.61" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</title>
        <description>All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.</description>
        <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MFF10</title>
            <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
          </group>
          <group group_id="O2">
            <title>F12M</title>
            <description>Formoterol fumarate 12 μg via pMDI/ Placebo via DPI</description>
          </group>
          <group group_id="O3">
            <title>F12D</title>
            <description>Placebo via pMDI/ Formoterol fumarate 12 μg via DPI</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo via pMDI/ Placebo via DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Serial Forced Vital Capacity (FVC) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</title>
          <description>All efficacy evaluations were based on spirometry assessments of lung function. FVC is the volume (liters) of air that can forcibly be blown out after full inspiration. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS / ERS standards.</description>
          <population>Full Analysis Set</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="2.04" upper_limit="2.14"/>
                    <measurement group_id="O2" value="2.09" lower_limit="2.05" upper_limit="2.14"/>
                    <measurement group_id="O3" value="2.09" lower_limit="2.04" upper_limit="2.13"/>
                    <measurement group_id="O4" value="2.08" lower_limit="2.03" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="2.07" upper_limit="2.17"/>
                    <measurement group_id="O2" value="2.11" lower_limit="2.06" upper_limit="2.16"/>
                    <measurement group_id="O3" value="2.11" lower_limit="2.06" upper_limit="2.16"/>
                    <measurement group_id="O4" value="2.08" lower_limit="2.03" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour (N=32, 31, 29, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="2.09" upper_limit="2.20"/>
                    <measurement group_id="O2" value="2.09" lower_limit="2.03" upper_limit="2.14"/>
                    <measurement group_id="O3" value="2.15" lower_limit="2.09" upper_limit="2.21"/>
                    <measurement group_id="O4" value="2.10" lower_limit="2.04" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="2.05" upper_limit="2.17"/>
                    <measurement group_id="O2" value="2.08" lower_limit="2.02" upper_limit="2.14"/>
                    <measurement group_id="O3" value="2.14" lower_limit="2.08" upper_limit="2.20"/>
                    <measurement group_id="O4" value="2.11" lower_limit="2.05" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="2.06" upper_limit="2.17"/>
                    <measurement group_id="O2" value="2.08" lower_limit="2.02" upper_limit="2.14"/>
                    <measurement group_id="O3" value="2.12" lower_limit="2.07" upper_limit="2.18"/>
                    <measurement group_id="O4" value="2.11" lower_limit="2.05" upper_limit="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="2.04" upper_limit="2.15"/>
                    <measurement group_id="O2" value="2.09" lower_limit="2.04" upper_limit="2.15"/>
                    <measurement group_id="O3" value="2.10" lower_limit="2.04" upper_limit="2.15"/>
                    <measurement group_id="O4" value="2.09" lower_limit="2.04" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="2.01" upper_limit="2.13"/>
                    <measurement group_id="O2" value="2.05" lower_limit="1.99" upper_limit="2.11"/>
                    <measurement group_id="O3" value="2.09" lower_limit="2.03" upper_limit="2.15"/>
                    <measurement group_id="O4" value="2.06" lower_limit="2.00" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</title>
        <description>All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards</description>
        <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MFF10</title>
            <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
          </group>
          <group group_id="O2">
            <title>F12M</title>
            <description>Formoterol fumarate 12 μg via pMDI/ Placebo via DPI</description>
          </group>
          <group group_id="O3">
            <title>F12D</title>
            <description>Placebo via pMDI/ Formoterol fumarate 12 μg via DPI</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo via pMDI/ Placebo via DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Serial Peak Expiratory Flow Rate (PEF) Measurement (i.e. at 5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose) Following Inhalation of a Single Dose of Study Medication to Evaluate the Onset and Duration of the Bronchodilatory Effect</title>
          <description>All efficacy evaluations were based on spirometry assessments of lung function. PEF is the greatest airflow rate achieved during forced exhalation with lungs fully inflated. At Visits 2, 3, 4 and 5, spirometry assessments were performed in the clinic at predose and again at 5 and 30 minutes and 1, 2, 4, 8 and 12 hours post-dose within ± 5 minutes of the scheduled time for the time points up to and including 60 minutes post-dose and then within ± 10 minutes for all subsequent time points. Spirometry equipment and performance of spirometric testing were in accordance with the ATS/ERS standards</description>
          <population>Full Analysis Set</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.65" lower_limit="238.31" upper_limit="254.99"/>
                    <measurement group_id="O2" value="248.17" lower_limit="239.72" upper_limit="256.63"/>
                    <measurement group_id="O3" value="250.05" lower_limit="241.48" upper_limit="258.62"/>
                    <measurement group_id="O4" value="237.85" lower_limit="229.40" upper_limit="246.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.69" lower_limit="245.56" upper_limit="265.81"/>
                    <measurement group_id="O2" value="253.37" lower_limit="243.14" upper_limit="263.59"/>
                    <measurement group_id="O3" value="257.81" lower_limit="247.48" upper_limit="268.14"/>
                    <measurement group_id="O4" value="243.59" lower_limit="233.36" upper_limit="253.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour (N=32, 31, 29, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.18" lower_limit="250.97" upper_limit="271.38"/>
                    <measurement group_id="O2" value="257.08" lower_limit="246.79" upper_limit="267.38"/>
                    <measurement group_id="O3" value="262.95" lower_limit="252.47" upper_limit="273.43"/>
                    <measurement group_id="O4" value="248.24" lower_limit="237.94" upper_limit="258.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.45" lower_limit="250.74" upper_limit="272.17"/>
                    <measurement group_id="O2" value="259.28" lower_limit="248.45" upper_limit="270.10"/>
                    <measurement group_id="O3" value="267.91" lower_limit="256.98" upper_limit="278.84"/>
                    <measurement group_id="O4" value="248.88" lower_limit="238.05" upper_limit="259.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.68" lower_limit="253.09" upper_limit="276.26"/>
                    <measurement group_id="O2" value="258.92" lower_limit="247.24" upper_limit="270.60"/>
                    <measurement group_id="O3" value="265.20" lower_limit="253.42" upper_limit="276.98"/>
                    <measurement group_id="O4" value="249.07" lower_limit="237.39" upper_limit="260.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.96" lower_limit="246.21" upper_limit="269.72"/>
                    <measurement group_id="O2" value="255.27" lower_limit="247.41" upper_limit="267.12"/>
                    <measurement group_id="O3" value="262.61" lower_limit="250.65" upper_limit="274.56"/>
                    <measurement group_id="O4" value="248.47" lower_limit="236.61" upper_limit="260.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.48" lower_limit="243.94" upper_limit="267.02"/>
                    <measurement group_id="O2" value="250.71" lower_limit="239.06" upper_limit="262.37"/>
                    <measurement group_id="O3" value="259.71" lower_limit="248.05" upper_limit="271.37"/>
                    <measurement group_id="O4" value="244.13" lower_limit="232.59" upper_limit="255.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)</title>
        <description>Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.</description>
        <time_frame>5, 30 Minutes and 1, 2, 4, 8 and 12 Hours Post-dose</time_frame>
        <population>Because of the dosing periods where formoterol was present at concentrations greater than 5% of the Cmax data for 4 subjects was excluded. A dosing error resulted in the exclusion of 1 subject and 1 subject had all data excluded from PK evaluation due to the plasma drug concentrations in conflict with the recorded randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>MFF10</title>
            <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
          </group>
          <group group_id="O2">
            <title>F12M</title>
            <description>Formoterol fumarate 12 μg via pMDI/ Placebo via DPI</description>
          </group>
          <group group_id="O3">
            <title>F12D</title>
            <description>Formoterol fumarate 12 μg via DPI/Placebo via pMDI</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Formoterol Concentrations (Pmol/L) Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)</title>
          <description>Unchanged racemic formoterol in plasma was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for plasma was 1.45 pmol/L. No non-compartmental PK analysis was performed.</description>
          <population>Because of the dosing periods where formoterol was present at concentrations greater than 5% of the Cmax data for 4 subjects was excluded. A dosing error resulted in the exclusion of 1 subject and 1 subject had all data excluded from PK evaluation due to the plasma drug concentrations in conflict with the recorded randomization.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Dose (N count MFF=15,F12M=17,F12D=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-10 minutes (N=16, 17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="12.2"/>
                    <measurement group_id="O2" value="16.3" spread="18.6"/>
                    <measurement group_id="O3" value="18.56" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes - 2 hours (N=16,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="12.2"/>
                    <measurement group_id="O2" value="24.7" spread="18.7"/>
                    <measurement group_id="O3" value="23.1" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours - 4 hours (N= 16, 17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="15.1"/>
                    <measurement group_id="O2" value="17.7" spread="10.5"/>
                    <measurement group_id="O3" value="17.4" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours - 8 hours (N= 16, 17, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="8.07"/>
                    <measurement group_id="O2" value="11.0" spread="5.3"/>
                    <measurement group_id="O3" value="11.3" spread="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours - 12 hours (N= 16, 16, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.74" spread="5.68"/>
                    <measurement group_id="O2" value="6.66" spread="5.7"/>
                    <measurement group_id="O3" value="6.83" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)</title>
        <description>Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.</description>
        <time_frame>0 to 3 hrs and 0-12 hrs</time_frame>
        <population>The pharmacokinetic population which was modified by the exclusion of dosing periods where formoterol was present at a concentration in excess of 5% of the Cmax.Five subjects were excluded due to various reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>MFF10</title>
            <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
          </group>
          <group group_id="O2">
            <title>F12M</title>
            <description>Formoterol fumarate 12 μg via pMDI/ Placebo via DPI</description>
          </group>
          <group group_id="O3">
            <title>F12D</title>
            <description>Formoterol fumarate 12 μg via DPI/Placebo via pMDI</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion of Formoterol Following a Single Dose of Formoterol Fumarate Alone and in Combination With Mometasone Furoate Via the pMDI and Formoterol Fumarate Via the Dry Powder Inhaler (DPI)</title>
          <description>Unchanged racemic formoterol in urine was assayed by LC-MS/MS. The lower limit of quantification (LLOQ) for urine was 0.0174 nmol/L expressed as free base. The amounts of unchanged formoterol excreted in urine from 0 to 3 hours (Ae0-3) and from 0 to 12 hours post-dose (Ae0-12) were calculated from the formoterol concentrations in urine and the urine volumes using non-compartmental methods.</description>
          <population>The pharmacokinetic population which was modified by the exclusion of dosing periods where formoterol was present at a concentration in excess of 5% of the Cmax.Five subjects were excluded due to various reasons.</population>
          <units>nmol</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae (0-3) nmol (N=15,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.20" upper_limit="0.49"/>
                    <measurement group_id="O2" value="0.52" lower_limit="0.33" upper_limit="0.80"/>
                    <measurement group_id="O3" value="0.42" lower_limit="0.27" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae (0-12) nmol (N=16,17,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="0.81" upper_limit="1.59"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.08" upper_limit="2.08"/>
                    <measurement group_id="O3" value="1.33" lower_limit="0.96" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>F12M</title>
          <description>Formoterol Fumarate 12 μg Via pMDI/ Placebo Via DPI</description>
        </group>
        <group group_id="E2">
          <title>F12D</title>
          <description>Placebo Via pMDI/ Formoterol Fumarate 12 μg Via DPI</description>
        </group>
        <group group_id="E3">
          <title>MFF10</title>
          <description>Formoterol fumarate 10μg/Mometasone furoate 100μg via pMDI</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo via pMDI/ Placebo via DPI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

